drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00346 | DB12010 | 472 | 214 | [
"DDInter44",
"DDInter785"
] | Alfuzosin | Fostamatinib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
472,
24,
214
]
],
[
[
472,
24,
723
],
[
723,
24,
214
]
],
[
[
472,
63,
600
],
[
600,
24,
214
]
],
[
[
472,
25,
1166
],
[
1166,
2... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluco... |
DB00497 | DB11901 | 828 | 913 | [
"DDInter1366",
"DDInter107"
] | Oxycodone | Apalutamide | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
828,
25,
913
]
],
[
[
828,
64,
600
],
[
600,
24,
913
]
],
[
[
828,
25,
609
],
[
609,
24,
913
]
],
[
[
828,
25,
1320
],
[
1320,
6... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} ... | Oxycodone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Oxycodone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a mode... |
DB00065 | DB10343 | 581 | 962 | [
"DDInter923",
"DDInter160"
] | Infliximab | Bacillus calmette-guerin substrain tice live antigen | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
581,
25,
962
]
],
[
[
581,
25,
617
],
[
617,
24,
962
]
],
[
[
581,
64,
1057
],
[
1057,
25,
962
]
],
[
[
581,
25,
1342
],
[
1342,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
... | Infliximab may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Infliximab may lead to a major life threatening interaction when taken with Etanercep... |
DB09564 | DB12267 | 1,296 | 1,476 | [
"DDInter930",
"DDInter233"
] | Insulin degludec | Brigatinib | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1296,
24,
1476
]
],
[
[
1296,
63,
1206
],
[
1206,
23,
1476
]
],
[
[
1296,
63,
629
],
[
629,
24,
1476
]
],
[
[
1296,
24,
1385
],
[
1385... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus... |
DB01611 | DB08868 | 1,487 | 1,011 | [
"DDInter893",
"DDInter737"
] | Hydroxychloroquine | Fingolimod | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1487,
25,
1011
]
],
[
[
1487,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1487,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
1487,
62,
1247
],
[
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Hydroxychloroquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Hydroxychloroquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Hydroxychloroquine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Hydroxychloroquine may cause a minor interaction that can limi... |
DB01611 | DB05541 | 1,487 | 801 | [
"DDInter893",
"DDInter239"
] | Hydroxychloroquine | Brivaracetam | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Moderate | 1 | [
[
[
1487,
24,
801
]
],
[
[
1487,
64,
477
],
[
477,
23,
801
]
],
[
[
1487,
63,
168
],
[
168,
23,
801
]
],
[
[
1487,
24,
1374
],
[
1374,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Borte... |
DB00341 | DB00404 | 1,242 | 523 | [
"DDInter343",
"DDInter54"
] | Cetirizine | Alprazolam | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Moderate | 1 | [
[
[
1242,
24,
523
]
],
[
[
1242,
24,
1418
],
[
1418,
40,
523
]
],
[
[
1242,
63,
905
],
[
905,
40,
523
]
],
[
[
1242,
24,
1408
],
[
1408,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Alprazolam (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Alprazolam (Compound)
Ceti... |
DB00619 | DB15982 | 1,419 | 1,339 | [
"DDInter909",
"DDInter193"
] | Imatinib | Berotralstat | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
1419,
24,
1339
]
],
[
[
1419,
62,
1101
],
[
1101,
23,
1339
]
],
[
[
1419,
23,
222
],
[
222,
23,
1339
]
],
[
[
1419,
24,
283
],
[
283,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine m... |
DB01176 | DB09272 | 537 | 412 | [
"DDInter453",
"DDInter632"
] | Cyclizine | Eluxadoline | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
537,
24,
412
]
],
[
[
537,
63,
1594
],
[
1594,
24,
412
]
],
[
[
537,
40,
830
],
[
830,
24,
412
]
],
[
[
537,
24,
849
],
[
849,
2... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cyclizine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that co... |
DB04946 | DB09472 | 924 | 1,383 | [
"DDInter907",
"DDInter1693"
] | Iloperidone | Sodium sulfate | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
924,
24,
1383
]
],
[
[
924,
64,
609
],
[
609,
24,
1383
]
],
[
[
924,
25,
1342
],
[
1342,
24,
1383
]
],
[
[
924,
25,
971
],
[
971,
... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"... | Iloperidone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iloperidone may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a... |
DB00515 | DB08889 | 589 | 350 | [
"DDInter387",
"DDInter299"
] | Cisplatin | Carfilzomib | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
589,
24,
350
]
],
[
[
589,
6,
4973
],
[
4973,
45,
350
]
],
[
[
589,
21,
28745
],
[
28745,
60,
350
]
],
[
[
589,
24,
1270
],
[
1270,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Cisplatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Cisplatin (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Carfilzomib (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00679 | DB00992 | 684 | 842 | [
"DDInter1796",
"DDInter1182"
] | Thioridazine | Methyl aminolevulinate (topical) | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
684,
24,
842
]
],
[
[
684,
21,
28787
],
[
28787,
60,
842
]
],
[
[
684,
36,
820
],
[
820,
63,
842
]
],
[
[
684,
40,
1178
],
[
1178,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Thioridazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Si... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Thioridazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Methyl aminolevulinate (Compound)
Thioridazine (Compound) resembles Alimemazine (Compound) and Thioridazin... |
DB01357 | DB12015 | 890 | 1,033 | [
"DDInter1160",
"DDInter53"
] | Mestranol | Alpelisib | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
890,
24,
1033
]
],
[
[
890,
62,
1130
],
[
1130,
24,
1033
]
],
[
[
890,
24,
1342
],
[
1342,
24,
1033
]
],
[
[
890,
63,
126
],
[
126,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Mestranol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pioglitazone"
],
[
... | Mestranol may cause a minor interaction that can limit clinical effects when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidep... |
DB00552 | DB14811 | 1,238 | 385 | [
"DDInter1425",
"DDInter979"
] | Pentostatin | Isatuximab | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
1238,
24,
385
]
],
[
[
1238,
24,
1362
],
[
1362,
24,
385
]
],
[
[
1238,
63,
377
],
[
377,
24,
385
]
],
[
[
1238,
74,
141
],
[
141,
... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin... |
DB00019 | DB09331 | 1,257 | 745 | [
"DDInter1405",
"DDInter478"
] | Pegfilgrastim | Daratumumab | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
1257,
24,
745
]
],
[
[
1257,
24,
4
],
[
4,
24,
745
]
],
[
[
1257,
24,
738
],
[
738,
63,
745
]
],
[
[
1257,
25,
1064
],
[
1064,
2... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesucc... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases ... |
DB05679 | DB08901 | 1,683 | 1,468 | [
"DDInter1907",
"DDInter1492"
] | Ustekinumab | Ponatinib | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1683,
24,
1468
]
],
[
[
1683,
63,
478
],
[
478,
24,
1468
]
],
[
[
1683,
24,
987
],
[
987,
63,
1468
]
],
[
[
1683,
24,
850
],
[
850,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 10... |
DB00331 | DB01404 | 1,645 | 757 | [
"DDInter1164",
"DDInter820"
] | Metformin | Ginseng | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1645,
24,
757
]
],
[
[
1645,
63,
245
],
[
245,
24,
757
]
],
[
[
1645,
24,
590
],
[
590,
24,
757
]
],
[
[
1645,
62,
1647
],
[
1647,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetoh... |
DB00748 | DB00794 | 662 | 759 | [
"DDInter297",
"DDInter1521"
] | Carbinoxamine | Primidone | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
662,
24,
759
]
],
[
[
662,
24,
697
],
[
697,
40,
759
]
],
[
[
662,
63,
362
],
[
362,
1,
759
]
],
[
[
662,
24,
157
],
[
157,
1,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Co... |
DB00556 | DB09104 | 1,262 | 286 | [
"DDInter1429",
"DDInter1118"
] | Perflutren | Magnesium hydroxide | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1262,
24,
286
]
],
[
[
1262,
24,
820
],
[
820,
23,
286
]
],
[
[
1262,
24,
688
],
[
688,
24,
286
]
],
[
[
1262,
25,
1593
],
[
1593,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol a... |
DB00363 | DB09039 | 695 | 1,670 | [
"DDInter419",
"DDInter629"
] | Clozapine | Eliglustat | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
695,
24,
1670
]
],
[
[
695,
25,
322
],
[
322,
24,
1670
]
],
[
[
695,
25,
119
],
[
119,
63,
1670
]
],
[
[
695,
24,
272
],
[
272,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",... | Clozapine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Clozapine may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate inte... |
DB00448 | DB01200 | 1,215 | 469 | [
"DDInter1022",
"DDInter243"
] | Lansoprazole | Bromocriptine | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
1215,
24,
469
]
],
[
[
1215,
6,
8374
],
[
8374,
45,
469
]
],
[
[
1215,
21,
28787
],
[
28787,
60,
469
]
],
[
[
1215,
63,
600
],
[
600,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Lansoprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound)
Lansoprazole (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluco... |
DB00762 | DB09020 | 613 | 28 | [
"DDInter973",
"DDInter212"
] | Irinotecan | Bisacodyl | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
613,
24,
28
]
],
[
[
613,
7,
2797
],
[
2797,
46,
28
]
],
[
[
613,
18,
6058
],
[
6058,
46,
28
]
],
[
[
613,
7,
6004
],
[
6004,
57... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Irinotecan",
"{u} (Compound) upregulates {v} (Gene)",
"ATF3"
],
[
"ATF3",
"{u} (Gene) is upregulated by {v} (Comp... | Irinotecan (Compound) upregulates ATF3 (Gene) and ATF3 (Gene) is upregulated by Bisacodyl (Compound)
Irinotecan (Compound) downregulates NCOA3 (Gene) and NCOA3 (Gene) is upregulated by Bisacodyl (Compound)
Irinotecan (Compound) upregulates RFC4 (Gene) and RFC4 (Gene) is downregulated by Bisacodyl (Compound)
Irinotecan ... |
DB00047 | DB08822 | 176 | 911 | [
"DDInter932",
"DDInter156"
] | Insulin glargine | Azilsartan medoxomil | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
176,
24,
911
]
],
[
[
176,
24,
217
],
[
217,
1,
911
]
],
[
[
176,
24,
1450
],
[
1450,
63,
911
]
],
[
[
176,
24,
549
],
[
549,
24... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmes... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a mod... |
DB06210 | DB11575 | 72 | 1,676 | [
"DDInter631",
"DDInter841"
] | Eltrombopag | Grazoprevir | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Major | 2 | [
[
[
72,
25,
1676
]
],
[
[
72,
63,
1419
],
[
1419,
24,
1676
]
],
[
[
72,
24,
351
],
[
351,
63,
1676
]
],
[
[
72,
63,
14
],
[
14,
25,
... | [
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib"... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribocic... |
DB11703 | DB14879 | 405 | 163 | [
"DDInter9",
"DDInter318"
] | Acalabrutinib | Cefiderocol | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.[FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to ... | Moderate | 1 | [
[
[
405,
24,
163
]
],
[
[
405,
64,
126
],
[
126,
24,
163
]
],
[
[
405,
63,
597
],
[
597,
24,
163
]
],
[
[
405,
64,
126
],
[
126,
63,... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefiderocol"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfa... | Acalabrutinib may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefiderocol
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenic... |
DB00685 | DB01067 | 1,299 | 959 | [
"DDInter1887",
"DDInter826"
] | Trovafloxacin | Glipizide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Major | 2 | [
[
[
1299,
25,
959
]
],
[
[
1299,
64,
245
],
[
245,
40,
959
]
],
[
[
1299,
25,
1411
],
[
1411,
1,
959
]
],
[
[
1299,
21,
29442
],
[
29442,
... | [
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
... | Trovafloxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Trovafloxacin may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Trovafloxacin (Compoun... |
DB00553 | DB00582 | 92 | 1,622 | [
"DDInter1177",
"DDInter1946"
] | Methoxsalen | Voriconazole | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
92,
24,
1622
]
],
[
[
92,
6,
8374
],
[
8374,
45,
1622
]
],
[
[
92,
21,
28997
],
[
28997,
60,
1622
]
],
[
[
92,
24,
663
],
[
663,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Methoxsalen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Methoxsalen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound)
Methoxsalen (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Voriconazole (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when t... |
DB00843 | DB01218 | 479 | 1,493 | [
"DDInter583",
"DDInter852"
] | Donepezil | Halofantrine | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Minor | 0 | [
[
[
479,
23,
1493
]
],
[
[
479,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
479,
18,
2183
],
[
2183,
57,
1493
]
],
[
[
479,
21,
28810
],
[
2881... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halofantrine"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Donepezil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Donepezil (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Donepezil (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by... |
DB00673 | DB00683 | 723 | 1,382 | [
"DDInter112",
"DDInter1212"
] | Aprepitant | Midazolam | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
723,
24,
1382
]
],
[
[
723,
63,
902
],
[
902,
40,
1382
]
],
[
[
723,
24,
1565
],
[
1565,
40,
1382
]
],
[
[
723,
6,
8374
],
[
8374,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam (Compound) resembles Midazolam (Compound)
Aprepi... |
DB11560 | DB11979 | 1,678 | 1,320 | [
"DDInter1038",
"DDInter625"
] | Lesinurad | Elagolix | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1678,
24,
1320
]
],
[
[
1678,
62,
168
],
[
168,
23,
1320
]
],
[
[
1678,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1678,
63,
79
],
[
79,
... | [
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Lesinurad",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"B... | Lesinurad may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat... |
DB00204 | DB00526 | 228 | 1,555 | [
"DDInter580",
"DDInter1355"
] | Dofetilide | Oxaliplatin | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
228,
25,
1555
]
],
[
[
228,
25,
79
],
[
79,
24,
1555
]
],
[
[
228,
25,
1213
],
[
1213,
63,
1555
]
],
[
[
228,
24,
384
],
[
384,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} ma... | Dofetilide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Dofetilide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interac... |
DB00307 | DB06077 | 1,101 | 879 | [
"DDInter202",
"DDInter1102"
] | Bexarotene | Lumateperone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Major | 2 | [
[
[
1101,
25,
879
]
],
[
[
1101,
24,
214
],
[
214,
63,
879
]
],
[
[
1101,
25,
1281
],
[
1281,
63,
879
]
],
[
[
1101,
24,
392
],
[
392,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostam... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Bexarotene may lead to a major life threatening interaction when taken with Linagliptin and Linagliptin ma... |
DB00448 | DB14491 | 1,215 | 428 | [
"DDInter1022",
"DDInter725"
] | Lansoprazole | Ferrous fumarate | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1215,
24,
428
]
],
[
[
1215,
24,
955
],
[
955,
23,
428
]
],
[
[
1215,
40,
379
],
[
379,
24,
428
]
],
[
[
1215,
24,
320
],
[
320,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mof... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Lansoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a... |
DB00153 | DB00776 | 1,331 | 1,335 | [
"DDInter662",
"DDInter1360"
] | Ergocalciferol | Oxcarbazepine | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1331,
24,
1335
]
],
[
[
1331,
24,
1605
],
[
1605,
1,
1335
]
],
[
[
1331,
6,
8374
],
[
8374,
45,
1335
]
],
[
[
1331,
21,
28972
],
[
289... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Oxcarbazepine (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Oxcarbazepine (Compound)
Ergocalciferol (Compound) causes Urine output increa... |
DB00748 | DB01224 | 662 | 623 | [
"DDInter297",
"DDInter1553"
] | Carbinoxamine | Quetiapine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
662,
24,
623
]
],
[
[
662,
63,
827
],
[
827,
1,
623
]
],
[
[
662,
24,
851
],
[
851,
1,
623
]
],
[
[
662,
6,
12523
],
[
12523,
45... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compou... |
DB00562 | DB06292 | 1,014 | 549 | [
"DDInter188",
"DDInter474"
] | Benzthiazide | Dapagliflozin | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1014,
24,
549
]
],
[
[
1014,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1014,
1,
811
],
[
811,
24,
549
]
],
[
[
1014,
63,
1179
],
[
1179,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Benzthiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01285 | DB14740 | 708 | 771 | [
"DDInter445",
"DDInter881"
] | Corticotropin | Hyaluronidase | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
708,
23,
771
]
],
[
[
708,
63,
1438
],
[
1438,
23,
771
]
],
[
[
708,
24,
35
],
[
35,
23,
771
]
],
[
[
708,
63,
1438
],
[
1438,
6... | [
[
[
"Corticotropin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Q... |
DB00697 | DB00927 | 876 | 1,559 | [
"DDInter1821",
"DDInter712"
] | Tizanidine | Famotidine | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Major | 2 | [
[
[
876,
25,
1559
]
],
[
[
876,
18,
4930
],
[
4930,
57,
1559
]
],
[
[
876,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
876,
23,
112
],
[
112,
... | [
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Famotidine"
]
],
[
[
"Tizanidine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Tizanidine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Famotidine (Compound)
Tizanidine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00850 | DB08881 | 1,630 | 868 | [
"DDInter1432",
"DDInter1925"
] | Perphenazine | Vemurafenib | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1630,
25,
868
]
],
[
[
1630,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1630,
7,
6952
],
[
6952,
46,
868
]
],
[
[
1630,
7,
6886
],
[
6886,
... | [
[
[
"Perphenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ve... | Perphenazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Perphenazine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Vemurafenib (Compound)
Perphenazine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Perph... |
DB05294 | DB09049 | 1,069 | 1,135 | [
"DDInter1917",
"DDInter1261"
] | Vandetanib | Naloxegol | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
1069,
23,
1135
]
],
[
[
1069,
64,
33
],
[
33,
23,
1135
]
],
[
[
1069,
25,
971
],
[
971,
62,
1135
]
],
[
[
1069,
25,
1618
],
[
1618,
... | [
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
... | Vandetanib may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Vandetanib may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a minor intera... |
DB00572 | DB00652 | 85 | 234 | [
"DDInter136",
"DDInter1421"
] | Atropine | Pentazocine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
85,
24,
234
]
],
[
[
85,
24,
1359
],
[
1359,
40,
234
]
],
[
[
85,
21,
28762
],
[
28762,
60,
234
]
],
[
[
85,
24,
537
],
[
537,
6... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[
"... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Atropine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Pentazocine (Compound)
Atropine may cause a moderate interaction that could... |
DB00662 | DB06691 | 717 | 849 | [
"DDInter1873",
"DDInter1155"
] | Trimethobenzamide | Mepyramine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
717,
24,
849
]
],
[
[
717,
63,
1594
],
[
1594,
24,
849
]
],
[
[
717,
24,
272
],
[
272,
24,
849
]
],
[
[
717,
24,
407
],
[
407,
6... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorph... |
DB00054 | DB01254 | 1,432 | 1,213 | [
"DDInter6",
"DDInter484"
] | Abciximab | Dasatinib | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1432,
25,
1213
]
],
[
[
1432,
23,
539
],
[
539,
62,
1213
]
],
[
[
1432,
24,
738
],
[
738,
63,
1213
]
],
[
[
1432,
24,
383
],
[
383,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may caus... |
DB00945 | DB05351 | 1,479 | 101 | [
"DDInter20",
"DDInter519"
] | Acetylsalicylic acid | Dexlansoprazole | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Minor | 0 | [
[
[
1479,
23,
101
]
],
[
[
1479,
24,
256
],
[
256,
62,
101
]
],
[
[
1479,
63,
1347
],
[
1347,
23,
101
]
],
[
[
1479,
25,
1468
],
[
1468,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pras... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00361 | DB11817 | 134 | 1,259 | [
"DDInter1939",
"DDInter165"
] | Vinorelbine | Baricitinib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
134,
25,
1259
]
],
[
[
134,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
134,
24,
949
],
[
949,
24,
1259
]
],
[
[
134,
24,
1129
],
[
1129,
... | [
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani tox... |
DB00213 | DB14491 | 837 | 428 | [
"DDInter1388",
"DDInter725"
] | Pantoprazole | Ferrous fumarate | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
837,
24,
428
]
],
[
[
837,
24,
955
],
[
955,
23,
428
]
],
[
[
837,
1,
379
],
[
379,
24,
428
]
],
[
[
837,
24,
320
],
[
320,
24,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mof... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Pantoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a... |
DB00675 | DB00927 | 888 | 1,559 | [
"DDInter1744",
"DDInter712"
] | Tamoxifen | Famotidine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
888,
24,
1559
]
],
[
[
888,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
888,
18,
1918
],
[
1918,
57,
1559
]
],
[
[
888,
21,
28803
],
[
2880... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Tamoxifen (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Tamoxifen (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Famotidine (Compound)
Tamoxifen (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Famotidine (Compound)
Tamoxifen... |
DB00835 | DB04908 | 100 | 1,671 | [
"DDInter245",
"DDInter741"
] | Brompheniramine | Flibanserin | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
100,
24,
1671
]
],
[
[
100,
24,
830
],
[
830,
24,
1671
]
],
[
[
100,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
100,
24,
407
],
[
407,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxyla... |
DB01138 | DB06779 | 804 | 365 | [
"DDInter1726",
"DDInter470"
] | Sulfinpyrazone | Dalteparin | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
804,
25,
365
]
],
[
[
804,
24,
1496
],
[
1496,
63,
365
]
],
[
[
804,
63,
121
],
[
121,
24,
365
]
],
[
[
804,
24,
557
],
[
557,
2... | [
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Ni... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine ... |
DB00675 | DB01156 | 888 | 593 | [
"DDInter1744",
"DDInter252"
] | Tamoxifen | Bupropion | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
888,
25,
593
]
],
[
[
888,
6,
3486
],
[
3486,
45,
593
]
],
[
[
888,
7,
12648
],
[
12648,
46,
593
]
],
[
[
888,
18,
2811
],
[
2811,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"... | Tamoxifen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bupropion (Compound)
Tamoxifen (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) is upregulated by Bupropion (Compound)
Tamoxifen (Compound) downregulates RRP1B (Gene) and RRP1B (Gene) is downregulated by Bupropion (Compound)
Tamoxifen (Compound)... |
DB00356 | DB01114 | 1,315 | 272 | [
"DDInter366",
"DDInter362"
] | Chlorzoxazone | Chlorpheniramine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1315,
24,
272
]
],
[
[
1315,
24,
849
],
[
849,
63,
272
]
],
[
[
1315,
24,
128
],
[
128,
24,
272
]
],
[
[
1315,
6,
12523
],
[
12523,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Dexbromph... |
DB00563 | DB01390 | 663 | 1,117 | [
"DDInter1174",
"DDInter1683"
] | Methotrexate | Sodium bicarbonate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
663,
23,
1117
]
],
[
[
663,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
663,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
663,
63,
1638
],
[
1638... | [
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) i... | Methotrexate (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken ... |
DB00502 | DB13074 | 1,300 | 877 | [
"DDInter853",
"DDInter1110"
] | Haloperidol | Macimorelin | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1300,
25,
877
]
],
[
[
1300,
23,
112
],
[
112,
23,
877
]
],
[
[
1300,
24,
85
],
[
85,
24,
877
]
],
[
[
1300,
25,
913
],
[
913,
2... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Haloperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atr... |
DB00619 | DB11866 | 1,419 | 1,068 | [
"DDInter909",
"DDInter1618"
] | Imatinib | Romosozumab | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
1419,
24,
1068
]
],
[
[
1419,
24,
1250
],
[
1250,
24,
1068
]
],
[
[
1419,
25,
1019
],
[
1019,
63,
1068
]
],
[
[
1419,
63,
251
],
[
251... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Imatinib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a m... |
DB00092 | DB15762 | 58 | 725 | [
"DDInter40",
"DDInter1644"
] | Alefacept | Satralizumab | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
58,
24,
725
]
],
[
[
58,
23,
1193
],
[
1193,
23,
725
]
],
[
[
58,
24,
1362
],
[
1362,
24,
725
]
],
[
[
58,
63,
599
],
[
599,
24,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olap... |
DB00586 | DB09061 | 1,512 | 1,627 | [
"DDInter537",
"DDInter284"
] | Diclofenac | Cannabidiol | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
1512,
24,
1627
]
],
[
[
1512,
24,
723
],
[
723,
23,
1627
]
],
[
[
1512,
63,
600
],
[
600,
23,
1627
]
],
[
[
1512,
24,
1613
],
[
1613,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flucon... |
DB08908 | DB11921 | 713 | 1,019 | [
"DDInter564",
"DDInter492"
] | Dimethyl fumarate | Deflazacort | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
713,
24,
1019
]
],
[
[
713,
24,
270
],
[
270,
63,
1019
]
],
[
[
713,
24,
200
],
[
200,
24,
1019
]
],
[
[
713,
63,
629
],
[
629,
... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Cand... |
DB00476 | DB09082 | 109 | 659 | [
"DDInter608",
"DDInter1934"
] | Duloxetine | Vilanterol | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
109,
24,
659
]
],
[
[
109,
25,
222
],
[
222,
24,
659
]
],
[
[
109,
63,
702
],
[
702,
24,
659
]
],
[
[
109,
24,
1674
],
[
1674,
2... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Duloxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may caus... |
DB00281 | DB00431 | 608 | 1,503 | [
"DDInter1066",
"DDInter1072"
] | Lidocaine | Lindane | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Moderate | 1 | [
[
[
608,
24,
1503
]
],
[
[
608,
21,
28999
],
[
28999,
60,
1503
]
],
[
[
608,
24,
143
],
[
143,
24,
1503
]
],
[
[
608,
63,
529
],
[
529,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis contact"
],
[
"Dermatitis contact",
"{u} (Side Ef... | Lidocaine (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Lindane (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mexiletine and Mexiletine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00341 | DB00906 | 1,242 | 1,567 | [
"DDInter343",
"DDInter1801"
] | Cetirizine | Tiagabine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
1242,
24,
1567
]
],
[
[
1242,
21,
28645
],
[
28645,
60,
1567
]
],
[
[
1242,
24,
530
],
[
530,
24,
1567
]
],
[
[
1242,
24,
537
],
[
537... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v}... | Cetirizine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Tiagabine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Cetiri... |
DB11652 | DB11837 | 1,155 | 1,297 | [
"DDInter1891",
"DDInter1351"
] | Tucatinib | Osilodrostat | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1155,
25,
1297
]
],
[
[
1155,
64,
1135
],
[
1135,
23,
1297
]
],
[
[
1155,
24,
466
],
[
466,
62,
1297
]
],
[
[
1155,
62,
222
],
[
222,
... | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Tucatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause ... |
DB00307 | DB06237 | 1,101 | 438 | [
"DDInter202",
"DDInter141"
] | Bexarotene | Avanafil | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Moderate | 1 | [
[
[
1101,
24,
438
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
438
]
],
[
[
1101,
21,
29118
],
[
29118,
60,
438
]
],
[
[
1101,
23,
1051
],
[
1051... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avanafil"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Avanafil (Compound)
Bexarotene (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Avanafil (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and... |
DB00679 | DB09564 | 684 | 1,296 | [
"DDInter1796",
"DDInter930"
] | Thioridazine | Insulin degludec | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
684,
24,
1296
]
],
[
[
684,
24,
274
],
[
274,
23,
1296
]
],
[
[
684,
25,
1621
],
[
1621,
23,
1296
]
],
[
[
684,
24,
1411
],
[
1411,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Thioridazine may lead to a major life threatening interaction when taken with Potassium chloride and P... |
DB00544 | DB00552 | 970 | 1,238 | [
"DDInter757",
"DDInter1425"
] | Fluorouracil | Pentostatin | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Moderate | 1 | [
[
[
970,
24,
1238
]
],
[
[
970,
54,
19218
],
[
19218,
15,
1238
]
],
[
[
970,
21,
28769
],
[
28769,
60,
1238
]
],
[
[
970,
62,
1467
],
[
14... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Fluorouracil",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Nucleic Acid Synthesis Inhibitors"
],
[
... | Fluorouracil (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class) and Nucleic Acid Synthesis Inhibitors (Pharmacologic Class) includes Pentostatin (Compound)
Fluorouracil (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Pentostatin (Compound)
... |
DB00845 | DB01128 | 1,490 | 918 | [
"DDInter406",
"DDInter204"
] | Clofazimine | Bicalutamide | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1490,
24,
918
]
],
[
[
1490,
24,
129
],
[
129,
40,
918
]
],
[
[
1490,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1490,
18,
16974
],
[
16974,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Clofazimine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Clofazimine (Compound) downregulates TUBB6 (Gene) and TU... |
DB00813 | DB08820 | 704 | 1,478 | [
"DDInter722",
"DDInter997"
] | Fentanyl | Ivacaftor | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
704,
24,
1478
]
],
[
[
704,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
704,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
704,
40,
307
],
[
307,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Fentanyl",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Fentanyl (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Fentanyl (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Fentanyl (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit cl... |
DB08815 | DB09038 | 154 | 1,450 | [
"DDInter1104",
"DDInter636"
] | Lurasidone | Empagliflozin | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
154,
24,
1450
]
],
[
[
154,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
154,
24,
1017
],
[
1017,
63,
1450
]
],
[
[
154,
25,
913
],
[
913,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib... |
DB00586 | DB00598 | 1,512 | 1,523 | [
"DDInter537",
"DDInter1013"
] | Diclofenac | Labetalol | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
1512,
24,
1523
]
],
[
[
1512,
24,
935
],
[
935,
1,
1523
]
],
[
[
1512,
24,
1274
],
[
1274,
63,
1523
]
],
[
[
1512,
21,
28719
],
[
2871... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Labetalol (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that co... |
DB00717 | DB01024 | 1,197 | 1,096 | [
"DDInter1312",
"DDInter1252"
] | Norethisterone | Mycophenolic acid | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Major | 2 | [
[
[
1197,
25,
1096
]
],
[
[
1197,
7,
18134
],
[
18134,
46,
1096
]
],
[
[
1197,
18,
2701
],
[
2701,
46,
1096
]
],
[
[
1197,
18,
4046
],
[
4... | [
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Norethisterone",
"{u} (Compound) upregulates {v} (Gene)",
"POLD4"
],
[
"POLD4",
"{u} (Gene) is upregulated by {v} (C... | Norethisterone (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Mycophenolic acid (Compound)
Norethisterone (Compound) downregulates CCNE2 (Gene) and CCNE2 (Gene) is upregulated by Mycophenolic acid (Compound)
Norethisterone (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) is downregulat... |
DB00357 | DB01229 | 1,051 | 973 | [
"DDInter71",
"DDInter1377"
] | Aminoglutethimide | Paclitaxel | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1051,
24,
973
]
],
[
[
1051,
24,
310
],
[
310,
63,
973
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
973
]
],
[
[
1051,
21,
28803
],
[
28803,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Am... |
DB00635 | DB09263 | 1,573 | 1,436 | [
"DDInter1515",
"DDInter1399"
] | Prednisone | Patiromer | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Moderate | 1 | [
[
[
1573,
24,
1436
]
],
[
[
1573,
1,
1220
],
[
1220,
24,
1436
]
],
[
[
1573,
40,
870
],
[
870,
24,
1436
]
],
[
[
1573,
23,
1114
],
[
1114,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a mo... | Prednisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01181 | DB08904 | 1,532 | 375 | [
"DDInter906",
"DDInter342"
] | Ifosfamide | Certolizumab pegol | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1532,
25,
375
]
],
[
[
1532,
63,
1461
],
[
1461,
23,
375
]
],
[
[
1532,
63,
704
],
[
704,
24,
375
]
],
[
[
1532,
24,
200
],
[
200,
... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vit... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fent... |
DB01144 | DB09080 | 1,326 | 144 | [
"DDInter540",
"DDInter1331"
] | Diclofenamide | Olodaterol | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1326,
24,
144
]
],
[
[
1326,
40,
504
],
[
504,
24,
144
]
],
[
[
1326,
25,
57
],
[
57,
24,
144
]
],
[
[
1326,
63,
1324
],
[
1324,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
... | Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Diclofenamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate i... |
DB08889 | DB12240 | 350 | 110 | [
"DDInter299",
"DDInter1485"
] | Carfilzomib | Polatuzumab vedotin | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
350,
24,
110
]
],
[
[
350,
63,
467
],
[
467,
24,
110
]
],
[
[
350,
24,
1480
],
[
1480,
24,
110
]
],
[
[
350,
24,
148
],
[
148,
6... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib... |
DB00524 | DB01105 | 811 | 222 | [
"DDInter1199",
"DDInter1665"
] | Metolazone | Sibutramine | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
811,
24,
222
]
],
[
[
811,
21,
28852
],
[
28852,
60,
222
]
],
[
[
811,
24,
659
],
[
659,
63,
222
]
],
[
[
811,
40,
1014
],
[
1014,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is c... | Metolazone (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Sibu... |
DB00374 | DB01136 | 1,061 | 772 | [
"DDInter1852",
"DDInter305"
] | Treprostinil | Carvedilol | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1061,
24,
772
]
],
[
[
1061,
18,
3576
],
[
3576,
45,
772
]
],
[
[
1061,
6,
6017
],
[
6017,
45,
772
]
],
[
[
1061,
7,
2966
],
[
2966,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (C... | Treprostinil (Compound) downregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Carvedilol (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carvedilol (Compound)
Treprostinil (Compound) upregulates HIF1A (Gene) and HIF1A (Gene) is bound by Carvedilol (Compound)
Treprostinil (Compound... |
DB00834 | DB01067 | 932 | 959 | [
"DDInter1215",
"DDInter826"
] | Mifepristone | Glipizide | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
932,
24,
959
]
],
[
[
932,
63,
245
],
[
245,
40,
959
]
],
[
[
932,
24,
1411
],
[
1411,
1,
959
]
],
[
[
932,
6,
8374
],
[
8374,
4... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB00218 | DB09104 | 1,176 | 286 | [
"DDInter1247",
"DDInter1118"
] | Moxifloxacin | Magnesium hydroxide | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1176,
24,
286
]
],
[
[
1176,
25,
820
],
[
820,
23,
286
]
],
[
[
1176,
23,
60
],
[
60,
23,
286
]
],
[
[
1176,
24,
1559
],
[
1559,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
... | Moxifloxacin may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecita... |
DB06605 | DB12267 | 1,409 | 1,476 | [
"DDInter108",
"DDInter233"
] | Apixaban | Brigatinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1409,
24,
1476
]
],
[
[
1409,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
1409,
24,
800
],
[
800,
24,
1476
]
],
[
[
1409,
25,
1598
],
[
1598... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"A... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may c... |
DB09065 | DB09074 | 760 | 1,362 | [
"DDInter424",
"DDInter1327"
] | Cobicistat | Olaparib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
760,
25,
1362
]
],
[
[
760,
63,
139
],
[
139,
24,
1362
]
],
[
[
760,
64,
588
],
[
588,
24,
1362
]
],
[
[
760,
24,
1619
],
[
1619,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Cobicistat may lead to a major life threatening interaction when taken with Methylergometrine and Methylergometrin... |
DB00881 | DB01050 | 954 | 848 | [
"DDInter1554",
"DDInter900"
] | Quinapril | Ibuprofen | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
954,
24,
848
]
],
[
[
954,
24,
1053
],
[
1053,
1,
848
]
],
[
[
954,
21,
28773
],
[
28773,
60,
848
]
],
[
[
954,
23,
286
],
[
286,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Quinapril (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Ibuprofen (Compound)
Quinapril may cause a minor ... |
DB00465 | DB00927 | 886 | 1,559 | [
"DDInter1010",
"DDInter712"
] | Ketorolac | Famotidine | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Minor | 0 | [
[
[
886,
23,
1559
]
],
[
[
886,
18,
10375
],
[
10375,
57,
1559
]
],
[
[
886,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
886,
1,
935
],
[
935,... | [
[
[
"Ketorolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Ketorolac",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} ... | Ketorolac (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Famotidine (Compound)
Ketorolac (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Ketorolac (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a minor interaction ... |
DB01244 | DB05812 | 762 | 1,374 | [
"DDInter192",
"DDInter8"
] | Bepridil | Abiraterone | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
762,
25,
1374
]
],
[
[
762,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
762,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
762,
62,
112
],
[
112,... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Abirateron... | Bepridil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Bepridil (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB01175 | DB06595 | 318 | 1,491 | [
"DDInter672",
"DDInter1214"
] | Escitalopram | Midostaurin | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
318,
25,
1491
]
],
[
[
318,
62,
112
],
[
112,
23,
1491
]
],
[
[
318,
64,
888
],
[
888,
24,
1491
]
],
[
[
318,
24,
1017
],
[
1017,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Escitalopram may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may c... |
DB00679 | DB01362 | 684 | 497 | [
"DDInter1796",
"DDInter960"
] | Thioridazine | Iohexol | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
684,
25,
497
]
],
[
[
684,
18,
6929
],
[
6929,
57,
497
]
],
[
[
684,
21,
28681
],
[
28681,
60,
497
]
],
[
[
684,
64,
999
],
[
999,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Thioridazine",
"{u} (Compound) downregulates {v} (Gene)",
"ITGAE"
],
[
"ITGAE",
"{u} (Gene) is downregulated by {v} (Compound)",... | Thioridazine (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Iohexol (Compound)
Thioridazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Thioridazine may lead to a major life threatening interaction when taken with Thieth... |
DB00242 | DB12941 | 1,064 | 466 | [
"DDInter392",
"DDInter481"
] | Cladribine | Darolutamide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
1064,
24,
466
]
],
[
[
1064,
24,
336
],
[
336,
23,
466
]
],
[
[
1064,
25,
351
],
[
351,
23,
466
]
],
[
[
1064,
25,
738
],
[
738,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Cladribine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause ... |
DB00685 | DB00731 | 1,299 | 1,144 | [
"DDInter1887",
"DDInter1269"
] | Trovafloxacin | Nateglinide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Major | 2 | [
[
[
1299,
25,
1144
]
],
[
[
1299,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
1299,
24,
1021
],
[
1021,
63,
1144
]
],
[
[
1299,
25,
870
],
[
8... | [
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nateglinide"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by ... | Trovafloxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00582 | DB05812 | 1,622 | 1,374 | [
"DDInter1946",
"DDInter8"
] | Voriconazole | Abiraterone | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1622,
24,
1374
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
1622,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1622,
23,
466
],
[
46... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Voriconazole (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolut... |
DB01192 | DB01619 | 560 | 830 | [
"DDInter1372",
"DDInter1441"
] | Oxymorphone | Phenindamine | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
560,
24,
830
]
],
[
[
560,
63,
537
],
[
537,
40,
830
]
],
[
[
560,
63,
13
],
[
13,
24,
830
]
],
[
[
560,
63,
104
],
[
104,
1,
... | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[... | Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction ... |
DB01044 | DB04868 | 246 | 478 | [
"DDInter809",
"DDInter1293"
] | Gatifloxacin | Nilotinib | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
246,
25,
478
]
],
[
[
246,
7,
18592
],
[
18592,
46,
478
]
],
[
[
246,
18,
5178
],
[
5178,
46,
478
]
],
[
[
246,
18,
10375
],
[
10375,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) upregulates {v} (Gene)",
"TMEM110"
],
[
"TMEM110",
"{u} (Gene) is upregulated by {v} (Compound)... | Gatifloxacin (Compound) upregulates TMEM110 (Gene) and TMEM110 (Gene) is upregulated by Nilotinib (Compound)
Gatifloxacin (Compound) downregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Nilotinib (Compound)
Gatifloxacin (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Nilotinib (Compo... |
DB01041 | DB01174 | 770 | 697 | [
"DDInter1789",
"DDInter1442"
] | Thalidomide | Phenobarbital | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
770,
24,
697
]
],
[
[
770,
63,
759
],
[
759,
1,
697
]
],
[
[
770,
63,
536
],
[
536,
40,
697
]
],
[
[
770,
6,
7950
],
[
7950,
45,... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Phenobarbital (... |
DB01254 | DB08875 | 1,213 | 1,618 | [
"DDInter484",
"DDInter262"
] | Dasatinib | Cabozantinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1213,
25,
1618
]
],
[
[
1213,
23,
1135
],
[
1135,
62,
1618
]
],
[
[
1213,
62,
112
],
[
112,
23,
1618
]
],
[
[
1213,
63,
723
],
[
723,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazo... |
DB09073 | DB15233 | 951 | 1,650 | [
"DDInter1379",
"DDInter142"
] | Palbociclib | Avapritinib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
951,
24,
1650
]
],
[
[
951,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
951,
24,
159
],
[
159,
24,
1650
]
],
[
[
951,
64,
908
],
[
908,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB00085 | DB13257 | 639 | 260 | [
"DDInter1384",
"DDInter727"
] | Pancrelipase | Ferrous sulfate anhydrous | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further informa... | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
639,
24,
260
]
],
[
[
639,
24,
1117
],
[
1117,
24,
260
]
],
[
[
639,
24,
1117
],
[
1117,
62,
752
],
[
752,
23,
260
]
],
[
[
639,
... | [
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium b... | Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Pancrelipase may cause a moderate interaction that could exacerbate diseases wh... |
DB08820 | DB12332 | 1,478 | 1,619 | [
"DDInter997",
"DDInter1626"
] | Ivacaftor | Rucaparib | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1478,
24,
1619
]
],
[
[
1478,
62,
307
],
[
307,
23,
1619
]
],
[
[
1478,
23,
271
],
[
271,
23,
1619
]
],
[
[
1478,
63,
1407
],
[
1407,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"M... | Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may ca... |
DB01200 | DB11186 | 469 | 1,609 | [
"DDInter243",
"DDInter1427"
] | Bromocriptine | Pentoxyverine | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
469,
24,
1609
]
],
[
[
469,
63,
104
],
[
104,
24,
1609
]
],
[
[
469,
24,
649
],
[
649,
24,
1609
]
],
[
[
469,
63,
104
],
[
104,
... | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
... | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Clofedan... |
DB01309 | DB13074 | 1,254 | 877 | [
"DDInter933",
"DDInter1110"
] | Insulin glulisine | Macimorelin | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1254,
24,
877
]
],
[
[
1254,
63,
1247
],
[
1247,
23,
877
]
],
[
[
1254,
63,
1020
],
[
1020,
24,
877
]
],
[
[
1254,
24,
388
],
[
388,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxa... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06788 | DB09038 | 1,616 | 1,450 | [
"DDInter864",
"DDInter636"
] | Histrelin | Empagliflozin | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1616,
24,
1450
]
],
[
[
1616,
63,
485
],
[
485,
24,
1450
]
],
[
[
1616,
24,
659
],
[
659,
63,
1450
]
],
[
[
1616,
64,
1327
],
[
1327,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vil... |
DB00024 | DB09564 | 818 | 1,296 | [
"DDInter1800",
"DDInter930"
] | Thyrotropin alfa | Insulin degludec | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cance... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
818,
24,
1296
]
],
[
[
818,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
818,
24,
1385
],
[
1385,
63,
1296
]
],
[
[
818,
24,
1411
],
[
1411,
... | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutami... | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00495 | DB00586 | 139 | 1,512 | [
"DDInter1961",
"DDInter537"
] | Zidovudine | Diclofenac | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
139,
24,
1512
]
],
[
[
139,
6,
8374
],
[
8374,
45,
1512
]
],
[
[
139,
21,
29231
],
[
29231,
60,
1512
]
],
[
[
139,
23,
752
],
[
752,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Zidovudine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound)
Zidovudine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetid... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.